Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

Recent & Breaking News (TSXV:VM)

Voyageur Pharmaceuticals announces $1M raise for contrast drug testing

Coreena Robertson October 29, 2024

Voyageur Announces Proposed Private Placement

Newsfile October 17, 2024

One of the best Venture pharma stocks has grown even stronger

Jonathon Brown October 3, 2024

Voyageur Pharmaceuticals Grants Stock Options

Newsfile September 25, 2024

Voyageur Pharmaceuticals Strengthens Leadership Team with Strategic Appointment of Dr. Ibrahim Hashmi as VP of Business Development

TheNewsWire September 24, 2024

Voyageur Pharmaceuticals Appoints Dr. Iryna Saranchova as Chief Science Officer, Enhancing the Company's Research and Innovation Leadership

TheNewsWire September 17, 2024

Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry

TheNewsWire September 5, 2024

Voyageur Pharmaceuticals Grants Deferred Share Units

TheNewsWire July 9, 2024

Revolutionizing medical imaging with nanocarbon-based contrast drugs

Jocelyn Aspa June 13, 2024

Testing to Begin of Radiology Endohedral Fullerenes, a Milestone in Nanotechnology & Drug Development

TheNewsWire June 11, 2024

Pharmaceuticals Co. grows global reach to meet unique medical need

Jonathon Brown June 5, 2024

Voyageur Pharmaceuticals signs $2.6M contract in Latin America

Jonathon Brown May 28, 2024

Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast

TheNewsWire May 28, 2024

Voyageur Pharmaceuticals Ltd Grants Deferred Share Units Compensation to Independent Directors

TheNewsWire April 3, 2024

Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options

TheNewsWire March 26, 2024

Voyageur Achieves Milestone with Rain Cage Royalty Agreement for Sustainable Carbon Drug Development

TheNewsWire March 13, 2024

Why carbon-based imaging drug advancement is the future of life sciences

Jocelyn Aspa March 12, 2024

Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement

TheNewsWire March 4, 2024

Voyageur Pharmaceuticals Ltd. Announces Closing of Private Placement

TheNewsWire March 1, 2024

Voyageur Pharmaceuticals Ltd. Announces Private Placement

TheNewsWire January 16, 2024